Talha Badar, a Specialist in Hematology Oncology based at Mayo Clinic, shared a post on X about a recent paper by Ada Antypiuk,

“Role of iron in pathophysiology of MDS, in a preclinical model.

Iron restriction improves erythropoiesis, limits myeloid expansion, and delays leukemia transformation.”

“Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study”

Authors: Ada Antypiuk, Zebulon Vance, Richa Sharma, Sara Passos, Michela Asperti, Shobana Navaneethabalakrishan, Franz Dürrenberger, Vania Manolova, Francesca Vinchi.

Role of iron in pathophysiology of MDS, in a preclinical model by Ada Antypiuk et al.

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.